Cart
sales@molnova.com
(R)-Zanubrutinib
CAS No. 1691249-44-1
(R)-Zanubrutinib( —— )
Catalog No. M33186 CAS No. 1691249-44-1
(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 78 | In Stock |
|
| 5MG | 73 | In Stock |
|
| 10MG | 136 | In Stock |
|
| 25MG | 226 | In Stock |
|
| 50MG | 333 | In Stock |
|
| 100MG | 457 | In Stock |
|
| 200MG | 635 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name(R)-Zanubrutinib
-
NoteResearch use only, not for human use.
-
Brief Description(R)-Zanubrutinib ((R)-BGB-3111) is a selective inhibitor of Bruton tyrosine kinase (BTK).
-
Description(R)-Zanubrutinib is the R enantiomer of Zanubrutinib. Zanubrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1691249-44-1
-
Formula Weight471.55
-
Molecular FormulaC27H29N5O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : ≥ 64.25 mg/mL (136.25 mM; Ethanol : < 1 mg/mL (insoluble)
-
SMILESNC(=O)c1c2NCC[C@H](C3CCN(CC3)C(=O)C=C)n2nc1-c1ccc(Oc2ccccc2)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wu J, et al. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016 Mar 9;9:21.?
molnova catalog
related products
-
Atuzabrutinib
Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.
-
BMS-986142
BMS-986142 (BMS 986142) is a potent, selective and reversible BTK inhibitor with IC50 of 0.5 nM.
-
Pirtobrutinib
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations.
